Boceprevir has been removed from the US market. It has not been studied in nursing mothers being treated for hepatitis C infection. Because it must be used with ribavirin and peginterferon alfa, it is not considered a good choice during breastfeeding. Until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. Hepatitis C is not transmitted through breastmilk and breastmilk has been shown to inactivate hepatitis C virus (HCV).[1–4] However, the Centers for Disease Control recommends that mothers with HCV infection should consider abstaining from breastfeeding if their nipples are cracked or bleeding. It is not clear if this warning would apply to mothers who are being treated for hepatitis C. Infants born to mothers with HCV infection should be tested for HCV infection; because maternal antibody is present for the first 18 months of life and before the infant mounts an immunologic response, nucleic acid testing is recommended.[1,4]
博赛匹韦已从美国市场撤下。尚未对接受丙型肝炎感染治疗的哺乳期母亲进行相关研究。由于它必须与利巴韦林和聚乙二醇干扰素α联合使用，因此在母乳喂养期间不被认为是一个好的选择。在有更多数据可用之前，可能更倾向于选择其他药物，尤其是在喂养新生儿或早产儿期间。丙型肝炎不会通过母乳传播，并且已证明母乳可使丙型肝炎病毒（HCV）失活[1 - 4]。然而，疾病控制中心建议，乳头皲裂或出血的丙型肝炎感染母亲应考虑避免母乳喂养。尚不清楚这一警告是否适用于正在接受丙型肝炎治疗的母亲。丙型肝炎感染母亲所生的婴儿应进行丙型肝炎感染检测；由于母体抗体在婴儿出生后的前18个月存在，且在婴儿产生免疫反应之前，建议进行核酸检测[1,4]。
